Uncategorized
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. IDE Trial for iStent infinite™
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient enrollment in its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trial for the iStent infinite™ Trabecular Micro-Bypass System. The iStent infinite is designed for use in a standalone procedure